

400 Garden City Plaza - Suite 300
 Garden City, New York 11530
 (516) 742-4343 - Telephone
 (516) 742-4366 - Facsimile
 e-mail: intprop@ssmp.com

**SCULLY, SCOTT, MURPHY
 & PRESSER, P.C.**

Fax

RECEIVED
 CENTRAL FAX CENTER
 FEB 21 2006


To:	To Whom It May Concern	From:	Peter I. Bernstein
Fax:	571-273-8300	Pages:	4 (including cover)
Phone:		Date:	February 21, 2006
Re:	Maria A. Pacciariini, et al. U.S. Patent Appln. No. 09/786,998 Our Docket: 17815 (PC28525A)		
	CC:		

Urgent **X For Review** **Please Comment** **Please Reply** **Please Recycle**

Dear Sirs:

Enclosed is a fax cover sheet, Examiner Interview Summary and Reference Abstract provided by Examiner Owens on September 27, 2005. Both Examiner Owens and Examiner Ana Jiang request that the enclosed materials be entered into the record of the above-referenced case as soon as possible.

If you have any questions or comments, please do not hesitate to contact us.

Sincerely,

 Peter I. Bernstein

CONFIDENTIALITY: The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right or publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.

If you have any problems concerning this facsimile, please call (516) 742-4343 and ask for Deb Gerber.



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

1 2006

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Fax Cover Sheet

Date: 27 Sep 2005

17815

To: Peter Bernstein	From: Howard V. Owens
Application/Control Number: 09/786,998	Art Unit: 1623
Fax No.: 5167424343	Phone No.: 571-272-0658
Voice No.:	Return Fax No.: (571)273-0658
Re:	CC:
<input type="checkbox"/> Urgent <input type="checkbox"/> For Review <input type="checkbox"/> For Comment <input type="checkbox"/> For Reply <input type="checkbox"/> Per Your Request	

Comments:

This fax includes a copy of the interview summary and the reference for which withdrawal of finality is based.

Number of pages 3 including this page

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

09/27/05 TUE 14:48 FAX

14002

Interview Summary	Application No.	Applicant(s)
	09/786,998	PACCIARINI ET AL.
	Examiner Howard V. Owens	Art Unit 1623

All participants (applicant, applicant's representative, PTO personnel):

**RECEIVED
CENTRAL FAX CENTER**

(1) Howard V. Owens. (3) _____. **FEB 21 2006**

(2) Peter Bernstein. (4) _____.

Date of Interview: 27 September 2005.

Type: a) Telephonic b) Video Conference
 c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
 If Yes, brief description: _____.

Claim(s) discussed: _____.

Identification of prior art discussed: Miura et al.Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The finality of the last office action will be withdrawn in order to present prior art by Miura et al., Gan To Kagaku Ryoho Aug 15(8 Pt. 2) pp. 2562-7 indicating that doxorubicin(as opposed to epirubicin) had been used in combination with lipiodol to treat liver cancer via intrahepatic administration.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an
Attachment to a signed Office action.

Examiner's signature, if required

09/27/05 TUE 14:48 FAX

4003

Entrez PubMed

Page 1 of 2



National
Library
of Medicine 

My NC
[Sign In] [Regis]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bool

Search PubMed

for

Limits Preview/Index History Clipboard Details

Display Abstract

20

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2562-7. Related Articles, Links

[Large-dose intra-arterial injection of lipiodol in liver cancer]

[Article in Japanese]

Takayasu Y, Kotake M, Takehara M, Taniguchi M, Nakao N, Miura T, Nakamura H.

Dept. of Radiology, Takarazuka City Hospital.

Effects of lipiodol (LPD) on liver functions were examined in 130 patients with primary and metastatic liver cancer who underwent TAE or intraarterial chemotherapy between May 1984 and March 1988 at our department and were available for follow-up studies. Effects of anticancer agents, particularly Adriamycin (ADM), were also evaluated. Large-dose intraarterial infusion of LPD had little effect on the liver functions of patients without liver cirrhosis but often caused a deterioration in liver functions of those with cirrhosis. A combination of this therapy with TAE using Gelfoam sponge caused only a temporary elevation in the transaminase level. The dose of ADM showed little association with the degree of liver disorders, unlike the case of cardiotoxicity or bone marrow suppression. Although the therapeutic effects of intraarterial infusion of ADM-LPD emulsion for advanced cancer (e.g., H4 and Vp3) such as improvements in the Vp factor are remarkable, the dose must be carefully determined, especially when liver cancer is complicated by liver cirrhosis.

Publication Types:

- Case Reports

PMID: 2843124 [PubMed - indexed for MEDLINE]

Display Abstract 20

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)